Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Viking Therapeutics, Inc. VKTX
$22.07
-$0.81 (-3.67%)
На 18:00, 12 мая 2023
-15.41%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2272344744.00000000
-
week52high
23.50
-
week52low
2.02
-
Revenue
0
-
P/E TTM
-26
-
Beta
0.76193700
-
EPS
-0.91000000
-
Last Dividend
0.00000000
-
Next Earnings Date
25 июл 2023 г. в 20:00
Описание компании
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 28 апр 2022 г. |
| Raymond James | Outperform | Outperform | 10 февр 2022 г. |
| Raymond James | Outperform | Outperform | 29 июл 2021 г. |
| Raymond James | Outperform | Strong Buy | 25 мая 2021 г. |
| Raymond James | Strong Buy | Strong Buy | 29 окт 2020 г. |
| Raymond James | Outperform | Outperform | 27 окт 2022 г. |
| Maxim Group | Buy | Buy | 20 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mancini Marianna | D | 317273 | 1079 | 15 янв 2023 г. |
| Lian Brian | D | 2272963 | 28619 | 04 янв 2023 г. |
| Mancini Marianna | D | 318352 | 13994 | 04 янв 2023 г. |
| ZANTE GREG | D | 185057 | 20708 | 04 янв 2023 г. |
| Lian Brian | D | 600000 | 600000 | 03 янв 2023 г. |
| Lian Brian | D | 2301582 | 68252 | 03 янв 2023 г. |
| Lian Brian | A | 2369834 | 266667 | 03 янв 2023 г. |
| Mancini Marianna | D | 204000 | 204000 | 03 янв 2023 г. |
| Mancini Marianna | D | 332346 | 18854 | 03 янв 2023 г. |
| Mancini Marianna | A | 351200 | 90667 | 03 янв 2023 г. |
Новостная лента
Why Viking Therapeutics Stock Wobbled Today
The Motley Fool
09 мая 2023 г. в 15:40
Viking Therapeutics' sizzling upswing took a slight breather this morning. However, most shareholders appear to have held on through today's volatility.
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
The Motley Fool
01 мая 2023 г. в 16:28
Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics were among the most volatile in the space.
Why Viking Therapeutics Stock Briefly Popped Today
The Motley Fool
27 апр 2023 г. в 14:56
H.C. Wainwright raised its price target on the biotech stock from $21 to $33 a share. Bullish investors on the stock seemingly took this as a strong buy signal.
Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript
Seeking Alpha
26 апр 2023 г. в 20:55
Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript.
3 Top Biotech Stocks Defying the Bear Market
The Motley Fool
25 апр 2023 г. в 08:45
TG Therapeutics' MS drug Briumvi has had strong early sales. Viking Therapeutics reports solid clinical results from its obesity drug VK2735.